RYTM
NASDAQRhythm Pharmaceuticals Inc.
Price$86.19-1.25 (-1.43%)
01:45 PM07:45 PM
News · 26 weeks59-56%
2026-04-192026-10-11
Mix2890d
- Insider8(29%)
- Other7(25%)
- Analyst5(18%)
- SEC Filings4(14%)
- Earnings3(11%)
- Leadership1(4%)
Latest news
25 items- ANALYSTWilliam Blair initiated coverage on Rhythm PharmaceuticalsWilliam Blair initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform
- PRRhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity -- BOSTON, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the commercial launch of IMCIVREE® (setmelanotide) in Japan to treat patients living with acquired hypothalamic obesity (HO), following its inclusion on Japan's National Health Insurance (NHI)
- SECSEC Form SCHEDULE 13G filed by Rhythm Pharmaceuticals Inc.SCHEDULE 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
- PRRhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic ObesityBOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Health Canada has approved IMCIVREE® (setmelanotide) for the additional indication of weight management in adult and pediatric patients 4 years of age and older with acquired hypothalamic obesity (HO). IMCIVREE was first approved by Health Canada in 2023 for weight management in adult and pediatric patients 6 years of age and older with obesity due to Bardet-Biedl syndrome (BBS), or genetically confirmed biallelic pro-opiomelanocortin (POMC), pro
- ANALYSTWolfe Research initiated coverage on Rhythm PharmaceuticalsWolfe Research initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform
- INSIDERPresident and CEO Meeker David P exercised 50,000 shares at a strike of $6.05 and sold $5,133,442 worth of shares (50,000 units at $102.67) as part of a pre-agreed trading plan (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- SECSEC Form 144 filed by Rhythm Pharmaceuticals Inc.144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
- ANALYSTLeerink Partners resumed coverage on Rhythm Pharmaceuticals with a new price targetLeerink Partners resumed coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $133.00
- PRRhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company’s work in rare melanocortin-4 receptor (MC4R) pa
- INSIDERChief Financial Officer Smith Hunter C exercised 57,187 shares at a strike of $25.79 and sold $6,619,913 worth of shares (62,774 units at $105.46) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 114,024 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- SECSEC Form 144 filed by Rhythm Pharmaceuticals Inc.144 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)
- ANALYSTDeutsche Bank initiated coverage on Rhythm Pharmaceuticals with a new price targetDeutsche Bank initiated coverage of Rhythm Pharmaceuticals with a rating of Hold and set a new price target of $120.00
- PRRhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination -- BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted marketing authorization to IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO). IMCIVREE, a melanocortin-4 receptor (MC4R) agonist which received orphan d
- INSIDERSEC Form 4 filed by Chief Medical Officer Joshi Manher4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERSEC Form 3 filed by new insider Joshi Manher3 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERChief Technical Officer Shulman Joseph exercised 2,024 shares at a strike of $6.80 and sold $608,210 worth of shares (5,079 units at $119.75) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 15,915 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDERChief Scientific Officer Garfield Alastair sold $912,703 worth of shares (7,763 units at $117.57) as part of a pre-agreed trading plan, decreasing direct ownership by 77% to 2,295 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- PRRhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical OfficerBOSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the appointment of Manher "AJ" Joshi, M.D., as Chief Medical Officer, effective August 17. "We are excited to welcome AJ to Rhythm as we enter a new stage of growth and continue to expand our global impact for patients living with rare neuroendocrine diseases," said David Meeker, M.D., Rhythm Chairman, President and Chief Executive Officer. "AJ brings more than two decades of leadership and experience from discovery through pivotal trials, global regu
- INSIDEREVP, Head of North America Lee Jennifer Kayden exercised 56,601 shares at a strike of $17.62 and sold $8,901,531 worth of shares (75,834 units at $117.38) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- INSIDEREVP, Head of International Mazabraud Yann exercised 46,625 shares at a strike of $6.80 and sold $6,620,575 worth of shares (57,000 units at $116.15) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 55,655 units (SEC Form 4)4 - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Issuer)
- PRRhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or ImpairmentBOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger in adults and children 4 years of age and older with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment. The MHRA this week also granted IMCIVREE orphan drug designation for acquired HO. "This authorization marks an
- SECSEC Form 10-Q filed by Rhythm Pharmaceuticals Inc.10-Q - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
- PRRhythm Pharmaceuticals Announces Participation in Upcoming Investor ConferencesBOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at three upcoming conferences. Hunter Smith will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Wednesday, August 12, 2026, 9:00 a.m. ET.David Meeker will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Bosto
- SECRhythm Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)
- PRRhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update-- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 ---- Second quarter 2026 net product revenue from global sales of IMCIVREE of $71.3 million ---- Weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in patients with acquired HO (n=7) after 16 weeks of treatment -- -- Phase 3 TRANSCEND Trial Results in Acquired HO published in the New England Journal of Medicine -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage b
RYTM FAQ
7 questionsWhat does Rhythm Pharmaceuticals Inc. do?
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities...Where does RYTM stock trade?
Rhythm Pharmaceuticals Inc. (RYTM) is listed on NASDAQ.What sector and industry is RYTM in?
Rhythm Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rhythm Pharmaceuticals Inc. go public?
Rhythm Pharmaceuticals Inc. (RYTM) completed its IPO in 2017.What are analysts saying about RYTM?
Rhythm Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-10-16.What companies are similar to RYTM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RYTM side-by-side with any of them on Quantisnow.How can I track RYTM on Quantisnow?
Quantisnow aggregates Rhythm Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RYTM to receive live email and push alerts on every new disclosure.